Skip to main content
. 2023 May 4;28(10):e930–e941. doi: 10.1093/oncolo/oyad121

Table 3.

Multivariate logistic model after initial SARS-CoV-2 vaccination.

Univariate logistic Multivariate logistic
Characteristic OR1 95% CI P value OR 95% CI P-value
Vaccine type (after two doses only)
 Moderna
 Pfizer 0.54 0.31, 0.91 .02 0.47 0.26, 0.86 .02
Diagnosis .03 .02
 CLL
 Other NHL 2.39 1.14, 5.31 .03 4.15 1.48, 13.4 .01
 WM 2.17 0.87, 5.91 .11 2.43 0.73, 9.11 .20
Age 1.01 0.98, 1.03 .60
Gender
 Female
 Male 0.83 0.49, 1.41 .50
Race
 White
 Other 1.17 0.58, 2.40 .70
Prior COVID infection (via PCR)
 No
 Yes 0.94 0.44, 2.06 .90
Prior COVID infection (via nucleocapsid-Ab)
 No
 Yes Inf 0.00, Inf NA
 Not tested 2.32 1.26, 4.36 .008
Prior/current cancer treatment
 No
 Yes 0.28 0.16, 0.49 <.001 0.68 0.20, 2.42 .50
BCL-2 inhibitor ever?
 No
 Yes 0.43 0.19, 0.94 .04 1.51 0.54, 4.26 .40
BTK inhibitor ever?
 No
 Yes 0.27 0.15, 0.47 <.001 0.51 0.17, 1.42 .20
CD20 mAb ever?
 No
 Yes 0.35 0.20, 0.58 <.001
Chemo and anti-CD20 ever?
 No
 Yes 0.53 0.26, 1.04 .07 0.70 0.26, 1.83 .50
CD20 mAb within 1 year of first vaccine dose? <.001 <.001
 Never
 Not within 1 year 0.60 0.33, 1.09 .10 0.83 0.30, 2.25 .70
 Yes 0.10 0.04, 0.25 <.001 0.11 0.03, 0.38 <.001

Abbreviation: OR, odds ratio.